|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C12N 15/60 | |
| C12N 15/63 | |||
| A61K 48/00 | |||
| C12N 9/88 | |||
| A61K 38/51 |
| (11) | Number of the document | 1631237 |
| (13) | Kind of document | T |
| (96) | European patent application number | 04776039.2 |
| Date of filing the European patent application | 2004-05-17 | |
| (97) | Date of publication of the European application | 2006-03-08 |
| (45) | Date of publication and mention of the grant of the patent | 2016-11-30 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2004/015662 |
| Date | 2004-05-17 |
| (87) | Number | WO 2004/110360 |
| Date | 2004-12-23 |
| (30) | Number | Date | Country code |
| 471300 P | 2003-05-16 | US | |
| 471239 P | 2003-05-16 | US | |
| 471240 P | 2003-05-16 | US | |
| 474372 P | 2003-05-29 | US |
| (72) |
GRUSKIN, Elliott, A., US
CAGGIANO, Anthony, O., US
ROY, Gargi, US
D`SOUZA, Rohini, US
|
| (73) |
Acorda Therapeutics, Inc.,
420 Saw Mill River Road, Ardsley, NY 10502,
US
|
| (54) | PROTEOGLYCAN DEGRADING MUTANTS FOR TREATMENT OF CNS |
| PROTEOGLYCAN DEGRADING MUTANTS FOR TREATMENT OF CNS |